IL-1Ra is naturally occurring anti-inflammatory antagonist of IL-1β that has recently been approved from FDA for the treatment of T2DM but due to its short half-life, higher dose with frequent dosing intervals are required. This evidence concerns the gene IL1B and type 2 diabetes mellitus.